Frost & Sullivan

AUGUST 29, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% However, the pharma/biopharma industry overall shows stagnant R&D activity. growth from 2023 to 2024. increase from 2022. Total R&D expenditure is approximately $276.81

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

Frost & Sullivan

MAY 3, 2023

4 th May 2023 – Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. SAN ANTONIO, TX. –

Contract research organization 52

Contract research organization Biopharmaceuticals Biopharma Business development 52

Frost & Sullivan

MARCH 22, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% However, the pharma/biopharma industry shows overall stagnant R&D activity. growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022.

Biopharma 52

Biopharma Ecosystems Biotech Contract research organization 52

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. years, to become a truly global company with a diverse mix of public sector and biopharma clients.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52